Palexia Depot

Tapentadol

Method of action: Analgesic

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Palexia Depot

Property	Description
Active ingredient	Tapentadol hydrochloride
Form	Prolonged-release tablet (Extended-release)
Pharmacological class	Opioid Analgesic; μ-Opioid Receptor/Noradrenaline Reuptake Inhibitor (MOR-NRI)
Origin	Synthetic
Common use	Management of severe, persistent pain requiring continuous treatment

Palexia Depot is a prescription-only, synthetic analgesic containing Tapentadol hydrochloride, specifically formulated to provide continuous relief from severe, long-term pain. This oral medication, originally developed by Grünenthal GmbH, is a single-agent product reserved for situations where alternative treatments for chronic discomfort are inadequate.

What Type of Medicine is Palexia Depot?

Palexia Depot is classified as a centrally-acting synthetic analgesic belonging to the μ-Opioid Receptor/Noradrenaline Reuptake Inhibitor (MOR-NRI) pharmacological class. Tapentadol is an active compound that does not rely on extensive metabolic activation by liver enzymes to exert its primary therapeutic effect.

The medication is supplied as an oral, prolonged-release tablet, a form that ensures the Tapentadol is released slowly and consistently over many hours. This sustained-release function is critical for maintaining steady blood concentrations, thereby supporting the goal of continuous pain management over a twenty-four-hour period.

The General Purpose of Dual-Action Pain Management

The primary purpose of Palexia Depot is to offer sustained, around-the-clock pain management for severe, persistent conditions. Tapentadol works by addressing pain through two simultaneous pathways in the central nervous system: it lessens the perception of intense pain signals by acting on the μ-opioid receptors, and it supports the body’s own descending pain control systems by inhibiting the reuptake of noradrenaline. This dual, synergistic mechanism provides a broad therapeutic approach for long-term chronic pain control.

What side effects are possible with Palexia Depot?

Possible side effects and safety information

Adverse Reaction Scope

The safety profile for tapentadol prolonged-release is predominantly defined by effects on the central nervous and gastrointestinal systems, as documented in regulatory sources like the EMA Summary of Product Characteristics (SmPC) and the FDA Prescribing Information.

The most frequently reported adverse reactions are classified by regulatory authorities as Very Common (occurring in 10% or more of patients), including dizziness, somnolence (drowsiness), headache, nausea, and constipation. Reactions classified as Common (1-10%) include vomiting, diarrhoea, decreased appetite, anxiety, sleep disorder, pruritus (itching), and fatigue.

Frequency Classification	Examples of Reactions	System Organ Classes Involved
Very Common	Dizziness, Nausea, Constipation, Somnolence	Nervous, Gastrointestinal
Rare	Respiratory depression, Convulsion, Drug dependence	Respiratory, Nervous, Psychiatric

Serious Safety Risks and Limitations

Official labeling highlights critical safety risks, including the potential for life-threatening respiratory depression, which is most likely to occur upon treatment initiation or following a dose increase. Tapentadol is associated with the risks of opioid addiction, abuse, and misuse and can cause Neonatal Opioid Withdrawal Syndrome (NOWS) if used for a prolonged time during pregnancy. The risk of Serotonin Syndrome is also noted, particularly when used in combination with other serotonergic agents.

Use is not recommended in patients with severe hepatic impairment or severe renal impairment. Furthermore, the drug is contraindicated in patients using Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their discontinuation. Safety and effectiveness have not been established in pediatric patients under 18 years of age.

Overdose and Emergency Response

Overdose of Tapentadol prolonged-release is documented in regulatory sources as a serious condition resulting from exaggerated mu-opioid receptor activity, potentially leading to life-threatening outcomes. The management of overdose requires immediate emergency intervention.

Documented Overdose Manifestations

Significant Respiratory Depression: The most severe manifestation, characterized by slowed or stopped breathing, is explicitly documented as a dose-related and potentially fatal sign of overdose.
CNS Depression: Clinical signs listed in labeling include profound sedation, coma, and a depressed level of consciousness.
Serotonin Risk: The possibility of a life-threatening Serotonin Syndrome is noted, particularly if the overdose involves co-ingestion with other serotonergic medicines.

Immediate Emergency Action Required

Regulatory documents mandate that users seek immediate medical attention or get emergency help right away upon any suspected overdose or accidental ingestion.

Fatal Risk from Tampering: Crushing, chewing, or dissolving the prolonged-release tablet releases a potentially fatal dose of Tapentadol, necessitating immediate emergency care.
Antidote Use: The opioid antagonist Naloxone is available for the emergency reversal of opioid-induced respiratory and CNS depression, and is managed alongside symptomatic and supportive treatment.
Pediatric Risk: Ingestion of even one tablet by a child is considered an immediate medical emergency due to the explicit risk of fatal overdose. Co-ingestion with CNS depressants is also noted to escalate the risk of death.

Therapeutic Uses of Palexia Depot

What Palexia Depot Treats: Main Uses and Benefits

Palexia Depot (tapentadol prolonged-release) is a prescription medication used for the management of severe chronic pain in adult patients. It is typically considered when other pain treatments, including non-opioid options, have proven inadequate to provide necessary pain control or cannot be tolerated. The primary therapeutic goal of this medication is to help patients achieve improved comfort and support better functional ability by addressing the persistent nature of severe discomfort.

The medication is specifically indicated for the management of severe, persistent pain that requires continuous, around-the-clock, long-term analgesic treatment. This includes the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN). The prolonged-release formulation is designed to offer a sustained therapeutic effect, contributing to the long-term relief of symptoms.

Quick Fact: Management of Severe, Persistent Pain

Palexia Depot is utilized to help reduce the intensity of severe, ongoing discomfort, including nerve-related pain, and support greater ease in daily activities.

Eligibility and Restrictions for Use

The use of Palexia Depot is strictly defined by regulatory eligibility rules, establishing the medicine for use only in adults (18 years of age and older). Safety and effectiveness have not been established in children and adolescents, and its use is not recommended in these populations.

Contraindications and Non-Eligibility

Use is absolutely contraindicated in patients with severe respiratory distress, including significant respiratory depression, acute or severe bronchial asthma, or hypercapnia. The medicine is also prohibited in any patient with a known or suspected paralytic ileus or who has used a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. Patients in a state of acute intoxication with alcohol or other centrally acting depressants must not use this medicine.

Restricted and Conditional Use

Eligibility is restricted based on organ function: use is not recommended for patients with severe hepatic impairment or severe renal impairment due to a lack of safety data. Individuals with moderate hepatic impairment require close monitoring and caution. During pregnancy, use is conditional; however, the medicine is not recommended for use while breastfeeding or immediately prior to labor and delivery.

What should I know about interactions with other medicines?

Palexia Depot (tapentadol extended-release) interacts with several classes of medications and substances, requiring careful medical oversight to prevent serious adverse effects.

Major Interaction Risks

Interacting Product Category	Key Risk	Required Action
Central Nervous System (CNS) Depressants (e.g., alcohol, benzodiazepines, gabapentinoids, other opioids, sedatives, some antihistamines, antipsychotics)	Profound sedation, life-threatening respiratory depression, coma, and death.	Use must be avoided or limited to the minimum effective dose for the shortest possible duration. Alcohol must be avoided completely.
Monoamine Oxidase Inhibitors (MAOIs)	Potential for serious cardiovascular events and heightened CNS effects.	Contraindicated (should not be used). Avoid using Palexia Depot within 14 days of taking an MAOI.
Serotonergic Medicinal Products (e.g., SSRIs, SNRIs, TCAs, triptans)	Risk of Serotonin Syndrome, a potentially life-threatening condition involving changes in mental status, involuntary muscle movements, and autonomic instability.	Requires close monitoring by a healthcare provider.

Mechanism of Action

Direct Central Inhibition of Nociceptive Signals

The molecule initiates its action by directly engaging the mu-Opioid Receptor ( MOR), a primary protein target in the central nervous system ( CNS). This engagement, or agonism, immediately activates an inhibitory signaling cascade, which results in a reduction in the release of neurotransmitters that propagate nociceptive messages. This molecular intervention reduces the transmission of signals within the ascending nociceptive pathway.

Augmenting Descending Inhibitory Control

Simultaneously, the molecule targets the Noradrenaline Transporter ( NET) by acting as an inhibitor. This action prevents the rapid clearance of the neurotransmitter noradrenaline from the synaptic cleft. The resultant increase in noradrenaline availability enhances the activity of the Descending Inhibitory Pain Pathway, thereby augmenting the central system's inhibitory control over afferent nociceptive input.

Synergy Through Dual Mechanism

The molecule’s profile is defined by the complementary synergy of these two independent actions ( MOR agonism and NRI). The MOR effect functions to restrict the transmission of nociceptive signals, while the NRI effect augments the endogenous descending inhibitory pathway. By targeting two distinct molecular and physiological pathways simultaneously, the dual mechanism produces a central inhibitory effect through the synergistic engagement of two distinct molecular pathways.

Dosage and Administration Information

How to Use Palexia Depot

Palexia Depot (tapentadol prolonged-release) is a prescription medicine administered orally as a tablet for the continuous, long-term management of severe pain. The prolonged-release tablets are designed to be taken on a twice-daily frequency pattern, typically every 12 hours, to maintain steady drug concentrations throughout the day.

Standard Administration and Dosage Rules

Instruction	Details (Official Use Protocol)
Starting Dose	Typically 50 mg administered twice daily for patients not currently taking opioids.
Titration Limit	Dose increases should not occur more frequently than every three days.
Maximum Dose	The maximum recommended daily dosage is 500 mg per day (250 mg twice daily).
Intake Condition	The medicine can be taken with or without food.

Procedural Constraints and Special Populations

To ensure the controlled release mechanism is maintained, the tablets must be swallowed whole, one at a time, using sufficient liquid. It is mandatory that the tablets not be cut, broken, chewed, crushed, or dissolved, as this could lead to the unintended rapid release of tapentadol.

Specific dosing modifications are required for certain patient groups. In cases of moderate hepatic impairment, the starting dose is reduced to 50 mg once daily, and the dose should not exceed 100 mg per day. The use of this medicine is not recommended in patients with severe hepatic or severe renal impairment (creatinine clearance <30 mL/min). When treatment is no longer required, the dose must be tapered gradually prior to full discontinuation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Palexia Depot

Palexia Depot (tapentadol prolonged-release) was evaluated in research exploring severe, persistent pain through a range of clinical research, including randomized controlled trials (RCTs) and long-term observational studies. This evidence base contributes to understanding what has been observed so far in the study populations and highlights what is known—and what is still uncertain—according to regulatory bodies and peer-reviewed scientific literature.

Evidence for Management of Severe Chronic Pain

Research exploring short-term symptom changes primarily involved RCTs that was studied for up to 15 weeks. These RCTs included adult patients who were experiencing pain severe enough to cause functional limitations. The outcomes examined included changes in patient-reported outcomes describing perceived discomfort and formal measures of daily functioning or activity level.

When compared against an active opioid control, the studies monitored for and reported patterns related to changes in pain intensity. Some trials described a pattern that was associated with differences in the rate of treatment discontinuations due to specific gastrointestinal issues when compared to the active control.

Evidence for Management of Neuropathic Pain

The evaluation included two specific randomized-withdrawal, placebo-controlled trials in adults diagnosed with chronic, painful Diabetic Peripheral Neuropathy (DPN). These studies research examined changes in average pain intensity and various measures related to neuropathic pain components.

The randomized-withdrawal trial design was used to examine the maintenance of measured outcomes among patients who had previously met the predefined criteria for symptom change. Findings contributed to the broader evidence landscape that informed regulatory conclusions for this condition.

Long-Term Data and Durability of Study Findings

To address durability, researchers used open-label extension studies that tracked patients who had met the predefined criteria for initial symptom change during the treatment for periods of up to 72 weeks. Data collected in routine clinical practice, from observational settings, research explored the use of the medicine for up to two years.

However, the long-term effects are not fully established based on blinded, controlled evidence. There is limited information for long-term outcomes because the maintenance of outcomes beyond 15 weeks relies primarily on uncontrolled, open-label extension studies.

Frequently Asked Questions (FAQ)

Common questions about Palexia Depot (FAQ)

Q: How long does it typically take to feel the effect of Palexia Depot?

Palexia Depot is a prolonged-release tablet designed to release the active ingredient slowly over time for continuous pain management. Regulatory information indicates that the immediate-release formulation reaches maximum concentrations in the blood within a short period after dosing.

The extended-release formulation, by contrast, is specifically designed to maintain consistent concentrations, supporting the goal of continuous relief throughout the day. Full pain-relieving effects may take some time to stabilize as the steady concentration of the medicine builds up in the system.

Q: What should I do if I forget to take a dose?

Official patient information describes a procedure where a forgotten dose can be taken as soon as it is remembered. If the time for the next scheduled dose is approaching, the prescribed protocol is generally to omit the forgotten dose and resume the usual schedule.

Regulatory patient guides specify that double doses are generally avoided to compensate for a missed dose. Consult the official patient information provided with your medicine for specific instructions.

Q: Are there different strengths of Palexia Depot available?

Yes, official product information indicates that Palexia Depot (tapentadol prolonged-release tablets) is available in multiple dosage strengths. The tablets are typically supplied in a range that includes 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg strengths.

The availability of multiple strengths supports tailored use based on therapeutic needs.

Q: Can I drive a car while taking Palexia Depot?

Regulatory documents caution that this medicine can affect the mental and physical abilities needed to perform potentially hazardous tasks, such as driving. This is due to common side effects like dizziness and somnolence (drowsiness).

Official guidance describes that patients should refrain from driving a car or operating heavy machinery until the individual response to the medicine is understood and it is confirmed that such tasks can be performed safely.

Q: Is there a maximum time a person can safely use this medicine?

Palexia Depot is officially indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Regulatory documents do not state a specific, absolute maximum duration for its use.

However, official guidance states that the continued need for this treatment and the corresponding dose must be evaluated by a healthcare professional on an ongoing basis.

Q: Does Palexia Depot cause high blood pressure?

Regulatory information indicates that Palexia Depot may cause hypotension (low blood pressure) in some patients. This includes the possibility of orthostatic hypotension, which is a sudden drop in blood pressure when standing up.

Conversely, high blood pressure is not commonly listed as a serious or frequent adverse reaction in the official product labeling.

How should Palexia Depot be stored and disposed of?

How to Store and Dispose of Palexia Depot

Storage and disposal requirements for Palexia Depot (tapentadol prolonged-release tablets) are strictly defined by regulatory documents, emphasizing safety due to its opioid classification.

Storage Requirements

This medicine does not require any special storage conditions regarding specific temperature ranges, light, or moisture restrictions prior to use.

Mandatory Safety Rule: Palexia Depot must be kept out of the sight and reach of children to prevent fatal accidental overdose. Tablets should be stored in the original container and the bottle must be kept tightly closed to maintain product integrity.

Disposal Instructions

Disposal of unused or expired tablets must be completed in accordance with local requirements. Official guidelines recommend utilizing drug take-back programs or authorized collection sites. Due to the high risk of misuse, if a take-back program is unavailable, some regulations mandate that the prolonged-release tablets be immediately flushed down the toilet rather than disposed of in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.